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Background: In westernized countries smoking and increasing age are the most important risk
factors for COPD. Prevalence and risk factors of COPD among non-smokers are not well studied.
Aim: To study the prevalence and risk factors of COPD among non-smokers and to determine
the proportion of non-smokers among subjects with COPD.
Methods: A random sample of 2470 subjects drawn from a population-based postal survey of
10,040 (85e88% participation) adults (aged 20e77) in Norrbotten, Sweden, were invited to
structured interviews and lung function tests, and 1897 participated. COPD was classified using
the fixed ratio (GOLD) definition and for comparison the lower limit of normal (LLN).
Results: The prevalence of airway obstruction was 6.9% among non-smokers and strongly age
related. The prevalence of GOLD stage II among non-smokers was 3.5%. Both among subjects
with airway obstruction and among subjects with GOLD stage II, the proportions of non-
smokers were 20%. Of men with airway obstruction, 14.1% were non-smokers versus 26.8%
among women. Non-smokers with GOLD stage II had significantly more symptoms and higher
co-morbidity than non-smokers without airway obstruction. Sex, area of domicile and exposure
to environmental tobacco smoke was not significantly associated to airway obstruction among
non-smokers. Using LLN for defining airway obstruction yielded a similar prevalence.esearch Centre, Department of Internal Medicine, Institute of Medicine, Sahlgrenska Academy,
-405 30, Gothenburg, Sweden. Tel.: þ46 31 786 6719, þ46 73 812 1137; fax: þ46 31 786 6730.
(S. Hagstad).
2 Elsevier Ltd. All rights reserved.
COPD among non-smokers 981Conclusion: The prevalence of airway obstruction among non-smokers was close to 7% and was
associated with increasing age. One out of seven men with airway obstruction, defined using
the fixed ratio, versus one out of four women had never smoked.
ª 2012 Elsevier Ltd. All rights reserved.Introduction
COPD is a major global health issue and is expected to be
the third most common cause of death worldwide by 2030.1
In westernized countries including Sweden, smoking and
increasing age are the most important risk factors for
COPD.2e5 In contrast, COPD is not uncommon among non-
smokers in developing countries where open fire stoves
are used for heating of houses and cooking.6 Until recently
COPD was regarded as an entirely environmental disease
with different air polluting sources being the most impor-
tant causal factor. Historically, COPD has been regarded as
either a predominantly emphysematous or predominantly
bronchitic.7 A more recent view is that both components
exist in varying degree in most subjects with COPD, and
today COPD is regarded as a syndrome with several clini-
cally different phenotypes.8
In clinically based settings it is not always obvious that
COPD also develops among never- smokers.9,10 In contrast,
epidemiological studies have identified a relatively large
proportion of subjects with COPD who never have been
smokers.2,11,12 It is not known whether COPD in non-
smokers constitute a specific phenotype, or if several
clinically important phenotypes of COPD may occur also
among non-smokers. Prevalence, clinical presentation
including severity of disease, and particularly risk factors of
COPD among never smokers are still not well studied.
Within the research program The Obstructive Lung
Disease in Northern Sweden (OLIN) Studies the epidemi-
ology of obstructive airway diseases has been studied since
1985.2,13e15 Results indicate COPD to be common in women
who never have been smokers.2,16 The aim of this study is to
investigate the prevalence and risk factors of COPD and the
clinical presentation of COPD among lifelong non-smokers.
A further aim is to compare COPD among non-smokers
with COPD among ever-smokers with regard to differences
in risk factors and clinical presentation.Materials and methods
Study population
The study population consisted of two randomly selected
samples of the responders to two postal questionnaire
surveys of the OLIN Studies.
The first cohort was invited in 1985/86, and consisted of
6610 subjects born in 1919e1920, 1934e1935 and
1949e1950 living in eight representative areas of the
Norrbotten County in Sweden.13 In 1996, this cohort
comprised 5933 subjects of whom 5892 could be traced.
These 5892 subjects were invited to a third survey where
5189 subjects responded. Of these responders, 1500subjects were randomly selected for a follow-up study. Out
of the 1500, 1282 participated in clinical examinations
including a structured interview, and 1237 performed lung
function tests with acceptable technique.2 In 1992 the third
cohort of the OLIN Studies was recruited from the same
area as the 1985/86 year cohort. Of 5681 invited subjects
aged 20e69 years, 4851 (85%) responded. A random sample
of the responders, 970 subjects, was invited to clinical
examinations in 1994/95, and 664 (68%) participated in
a structured interview, and 660 subjects performed
acceptable lung function tests.5 Identical methods and
techniques were used in the 1994/95 and the 1996 studies,
and the data from the two studies have been pooled.
The study was approved by the ethical committee at the
University Hospital of Northern Sweden in Umea˚.
Methods
Structured interview
The questionnaire consisted of questions about respiratory
symptoms, use of medications, smoking habits, socio-
economic status, history of exposure to environmental
tobacco smoke and family history of obstructive airway
diseases.13 The original questionnaire was developed in
1985 for the first OLIN survey mainly from the respiratory
questionnaires of the British Medical Research Council
(MRC), the International Union Against Tuberculosis and
Lung Diseases (IUATLD) and the questionnaires used at the
US Tucson, Arizona studies, and has been used with minor
modifications in all surveys of the OLIN cohorts among
adults. Furthermore has it later been used in several other
Swedish and Northern European studies.17e20 The inter-
views and the lung function tests as well were performed by
specially trained nurses.
Lung function tests
The lung function tests were performed using a dry
spirometer (Mijnhardt Vicatest 5, The Netherlands). The
tests were performed following the ATS guidelines. Swedish
reference values that have been found to conform well to
the symptom-free population of the OLIN-studies were
used.21 A reversibility test using 0.8 mg salbutamol (Ven-
toline Discus) was performed in all subjects having either
a ratio of FEV1/FVC or VC <0.7 or FEV1 <90% of the pre-
dicted value.
Definitions
COPD was classified using the fixed ratio definition and
disease severity staging according to the Global Initiative of
COPD (GOLD) guidelines.22 In this study, clinically relevant
COPD was defined as GOLD stage II, as several medical
conditions are associated with a FEV1/FVC <0.70 and
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982 S. Hagstad et al.a normal FEV1.23 Presence of a post-bronchodilator ratio of
FEV1/FVC <0.70 was termed airway obstruction. For
comparison, airway obstruction was defined also by using
the lower limit of normal (LLN). For defining LLN, the
equation by Viljanen et al., Finland,24 in which the LLN has
been estimated at 88% of predicted for both men and
women. Our study population, as well as the study area, is
climatologically similar to Finland.
Non-smokers were defined as those who had smoked on
average <1 cigarette/day for <1 year or had never smoked.
Ex-smokers were defined as subjects who had ceased
smoking at least 12 months prior to the interview. Ever-
smokers refer to either current or ex-smokers. Urban areas
were defined as having >10,000 inhabitants, small towns
2000e9999 and rural areas as <2000 inhabitants. Socio-
economic status was based on reported occupation
according to definitions by Statistics Sweden. Subjects who
reported previous or current history of angina pectoris,
myocardial infarction or congestive heart failure were
referred to as “any cardiac disease”.
A subject who reported wheezing at any time 12 months
prior to the study was defined as having “any wheeze”.
Dyspnoea was graded according to the modified Medical
Research Council dyspnoea scale and significant dyspnoea
was regarded as grade 2 or higher.25 Any nasal symptom was
considered positive if the subject reported a history of
rhinitis, nasal congestion or nasal polyps. Family history of
obstructive airway disease was considered positive in those
subjects who reported a first-degree relative with asthma,
chronic bronchitis, emphysema or COPD. Use of medication
for obstructive airway disease was considered positive if
the subject reported past or present use of any asthma- or
other bronchodilating medication. History of environmental
tobacco smoke during childhood was considered positive if
at least one person in the household was a habitual indoor
smoker during the subject’s childhood. Other pulmonary
disease was considered positive if the subject reported any
pulmonary disease apart from obstructive airway disease
(asthma, chronic bronchitis or emphysema).
Contact with health care was considered to have
occurred if the subject reported having either sought
medical attention for respiratory symptoms other than
common cold, to have visited the emergency room for
respiratory symptoms, or to have been admitted due to
respiratory illnesses.T
a
b
le
1
Sm
o
ki
n
g
h
a
b
it
s
b
y
a
ge
a
n
d
se
x
(%
).
5
0
ye
a
rs
M
F
(N
)
45
0
48
2
N
o
n
-s
m
o
ke
rs
(%
)
36
.2
39
.2
E
x-
sm
o
ke
rs
(%
)
36
.2
26
.3
C
u
rr
e
n
t
sm
o
ke
rs
(%
)
27
.6
34
.4
B
o
ld
te
xt
in
d
ic
a
te
s
st
a
ti
st
ic
a
l
si
gn
ifi
ca
n
ce
.
a
T
e
st
fo
r
tr
e
n
d
co
m
p
a
ri
n
g
sm
o
ki
n
g
st
a
tu
s
b
y
a
b
C
o
m
p
a
ri
n
g
sm
o
ki
n
g
st
a
tu
s
b
y
se
xAnalyses
Statistical analyses were performed using the statistical
package for the social sciences (PASW) version 18. Fisher’s
exact test was used for bi-variate comparisons between
groups and ManteleHaenzsel was used for test for trend.
Consistently, a p-value of <0.05 was considered significant.
Calculations of odds ratios (OR) and 95% confidence
intervals (CI) were performed using multiple logistic
regression analysis with dependent variables airway
obstruction and GOLD stage II in non-smokers. The inde-
pendent variables included sex, age group, area of domi-
cile, socio-economic group and exposure to environmental
tobacco smoke (ETS) at home, family history of obstructive
airway disease and previous physician diagnosis of asthma.
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Fig. 1 Prevalence (%) of airway obstruction in ever- and
never-smokers, respectively, by disease severity. Difference
(p-value) between ever- and non-smokers.
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Fig. 2 Distribution (%) of COPD by GOLD severity stages
among non-smoking men and women. Test for trend compar-
ison between men and women.
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Participation by smoking habits and prevalence of
airway obstruction
Seven hundred and ninety-eight non-smokers completed
the interview and 770 (96.5%) the lung function tests. By
comparison 653 ex-smokers and 492 current smokers
completed the interview and 646 (98.9%) ex-smokers and
480 (97.6%) current smokers performed lung function tests.
Among all participating subjects, 41.1% were non-smokers.
Never-smoking was more common among women in all age
groups, although this gender difference was decidedly less
marked in the youngest age group. Ex-smokers were
predominately male, while there was no gender difference
among current smokers (Table 1).
Of non-smokers 6.9% (6.6% among men; 7.0% women;
n.s.) had airflow obstruction according to the GOLD spiro-
metric criteria compared to 15.2% among ex-smokers and
23.8% among current smokers (p< 0.001).
The prevalence of COPD GOLD stage II was 3.5% among
non-smokers versus 7.4% among ex-smokers and 13.1%
among current smokers (p< 0.001). Overall, the prevalence
of airflow obstruction was 14.0% and of GOLD stage II 7.3%
(Fig. 1). Of the 53 non-smokers with airflow obstruction,
there were 26 subjects with GOLD stage I, 21 with GOLD
stage II, 5 with GOLD stage III, and 1 subject with GOLD
stage IV (Table 2).
Altogether, among all subjects fulfilling the GOLD
spirometric criteria of airway obstruction, non-smokersTable 2 Prevalence (%) of airway obstruction among non-smoke
women. Difference (p-value) by age and sex.
50 years 51-65 years 66 years
M W M W M W
(N) 160 185 106 172 35 11
GOLD I 2.5 1.1 5.7 2.3 8.6 6
GOLD II 1.3 2.2 0.9 2.3 8.6 6
GOLD III/IV 0 0.5 0 0.6 2.9 2
All COPD 3.8 3.8 6.6 5.2 20.0 15
Bold text indicates statistical significance.
a Test for trend comparing disease severity by each GOLD stage res
b Comparing disease severity by each GOLD stage respectively andaccounted for 20.0%. Correspondingly, among subjects
with GOLD stage II non-smokers accounted for 19.6%. By
gender, 14.1% of men with airflow obstruction were non-
smokers versus 26.8% of women (pZ 0.013) (Fig. 2). Among
non-smokers a significant association (p< 0.001) between
increasing age and prevalence of airflow obstruction was
found (Table 2).
Relation to socio-economic status and
environmental tobacco smoke
No significant difference between non-smokers without
airflow obstruction and the subjects with GOLD stage II
was found in socio-economic status, area of domicile and
exposure to ETS, apart from exposure to tobacco smoke at
current workplace, which was less common among the
subjects with GOLD stage II than those without airflow
obstruction. Regarding socio-economic status, there was
a trend of a greater proportion of ever-smokers in manual
workers in industry (Table 3).
Respiratory symptoms and co-morbidity in non-
smokers with COPD
When comparing non-smokers with versus without airflow
obstruction a trend was noted towards more symptoms and
higher co-morbidity. However, this was not entirely of
statistical significance. When comparing the non-smokers
with GOLD stage I with those without airflow obstruction, nors by age group and disease severity (GOLD stage) in men and
All ages p-Value
M W Total (n) By agea By sexb
2 301 469 770
.3 2.8 2.8 26 0.003 0.309
.3 2.0 3.2 21 0.004 0.372
.7 0.3 1.1 6 0.010 0.413
.2 6.6 7.0 53 <0.001 0.885
pectively and age group.
sex.
Table 3 Demographic and exposure characteristics (%): exposure to environmental tobacco smoke, socio-economic status and
area of domicile by smoking habits and presence of GOLD stage II. Difference (p-value) by having GOLD stage II or not having
airway obstruction (AO) in non-smokers and ever-smokers, respectively.
Variables Categories Non-smokers Ever-smokers
Not AO GOLDII p-Valuea Not AO GOLDII p-Valueb p-Valuec
(N) 717 27 914 111
Exposure to
environmental
tobacco smoke
At home 39.0 37.0 1.000 85.7 92.8 0.039 <0.001
At current workplace 28.0 7.4 0.015 41.2 30.9 0.039 0.014
At previous workplace 68.6 70.8 1.000 76.3 86.5 0.018 0.072
At home during childhood 52.7 40.7 0.244 64.0 46.8 0.001 0.668
Socio-economic
status
Manual workers in industry 17.5 13.0 0.648d 22.8 31.8 0.155d 0.566d
Manual workers in service 29.7 34.8 26.7 28.0
Non-manual assistant employees 15.4 30.4 15.3 10.3
Civil servants and academics 28.3 13.0 27.4 16.8
Self-employed and others 9.1 8.7 7.7 13.1
Area of domicile Urban 60.6 42.3 0.266d 60.4 58.7 0.680d 0.319d
Small town 22.6 42.3 25.5 25.7
Rural area 16.8 15.8 14.2 15.6
Bold text indicates statistical significance.
a Not AO versus GOLDII in non-smokers.
b Not AO versus GOLDII in ever-smokers.
c GOLDII in non-smokers versus ever-smokers.
d Test for trend.
984 S. Hagstad et al.difference was found in symptoms or co-morbidity (data not
shown). After stratifying by disease severity and comparing
the non-smokers with GOLD stage II and those without
airflowobstruction, significantlymore symptomsandahigher
ratio of co-morbidity was found. In addition a prior diagnosis
of asthma, but not of chronic bronchitis or emphysema, was
significantly more common among subjects with GOLD stage
II in non-smokers (Table 4). Current or prior use of medi-
cation for obstructive airway diseasewas alsomarkedlymore
common among the non-smokers with GOLD stageII (59.3%)
than those without airflow obstruction (16.6%).
Of non-smokers with GOLD stage II, 40.7% had a prior
diagnosis of asthma and 11.1% had a prior diagnosis of
chronic bronchitis or emphysema. Among ever-smokers
with the same disease severity 29.7% had a prior diagnosis
of asthma and 27.9% a diagnosis of chronic bronchitis or
emphysema. History of tuberculosis was significantly more
common among the ever-smokers with GOLD stage II
compared to those without airway obstruction, but there
was no significant difference in the never-smoking group. A
family history of obstructive airway disease was signifi-
cantly more prevalent among subjects with GOLD stage II
compared to subjects without airway obstruction (Table 4).
Risk factors for COPD among non-smokers
The most predominant risk factor for airway obstruction
among non-smokers was increasing age. Further, a previous
diagnosis of asthma was an independent risk factor for
airway obstruction among non-smokers and among the
subjects with GOLD stage II. A family history of obstruc-
tive airway disease remained a significant risk factor for
GOLDII also in the multivariate setting. Sex, area of
domicile, socio-economic status and exposure for ETS at
home failed to reach statistical significance (Table 5).Airway obstruction defined by LLN
We found the prevalence of airway obstruction among
non-smokers to be 52/770 (6.8%) by using the LLN as
a criterion for obstruction. In comparison to the GOLD
criteria, eight elderly subjects were not classified as
having airway obstruction when using the LLN-criterion,
while seven younger subjects became classified as having
obstruction. The distribution by gender and severity was
similar. When using multivariate logistic regression risk
analysis, age >65 years versus age 50 years yielded an OR
of 2.20 (95% CI 1.11e4.40) and physician-diagnosed
asthma an OR of 2.43 (95% CI 1.18e5.00). Thus both age
and asthma remained independent risk factors for airway
obstruction in never-smokers, but the odds ratios was
lower in comparison with obstruction defined by using the
fixed ratio.Discussion
In our study non-smokers accounted for 20% of all subjects
with airway obstruction. This is in line with previous results
from the US NHANES III study (25%), the Austrian part of the
BOLD study (18%), and the ECRHS (17%),11,26,27 although
lower when compared to studies from developing countries
and regions such as the Chinese CESCOPD study (39%) and
the Columbian PREPOCOL study (38%) where use of biomass
fuel and tuberculosis is considerably more common than in
Europe and USA.28,29
Using both the fixed ratio of FEV1/VC below 0.7 and the
lower limit of normal (LLN) for defining airway obstruction
yielded a similar prevalence, about 7%, of obstruction in
never-smokers. As expected, somewhat fewer subjects
among the elderly and slightly more among the younger
Table 4 Respiratory symptoms, co-morbidity, family history of obstructive airway disease, health care consumption and
previous physician diagnosis of obstructive airway disease by smoking status and disease severity (%). Difference (p-value) by
having or not having GOLD stage II or not having airway obstruction (AO) in non-smokers and ever-smokers, respectively.
Symptom or condition Non-smokers Ever-smokers
Not AO GOLDII p-Valuea Not AO GOLDII p-Valueb p-Valuec
(N) 717 27 914 111
Sputum production 19.4 55.6 <0.001 25.2 61.3 <0.001 0.663
Long-standing cough 42.8 81.5 <0.001 47.4 80.2 <0.001 1.000
Chronic productive cough 5.6 11.1 0.201 10.3 19.8 0.006 0.407
Recurrent wheeze 19.5 55.6 <0.001 27.4 69.4 <0.001 0.180
Any wheeze 25.7 59.3 <0.001 37.6 73.0 <0.001 0.168
Dyspnoea 10.5 33.3 0.002 9.2 41.4 <0.001 0.515
History of rhinitis 21.3 25.9 0.632 16.5 15.3 0.892 0.255
Any nasal symptoms 39.2 59.3 0.045 40.5 40.5 1.000 0.088
History of cardiac disease 7.8 22.2 0.019 9.5 22.5 <0.001 1.000
Hypertension 24.8 25.9 0.825 19.4 35.1 <0.001 0.495
Respiratory disease during childhood 18.5 33.3 0.076 18.8 17.1 0.796 0.106
History of TBC 2.4 3.7 0.490 2.1 6.3 0.017 1.000
History of other pulmonary disease 24.7 51.9 0.003 27.7 51.4 <0.001 1.000
Previous physician diagnosis of asthma 9.6 40.7 <0.001 9.6 29.7 <0.001 0.357
Previous physician diagnosis of chronic
bronchitis/emphysema
4.2 11.1 0.113 6.2 27.9 <0.001 0.083
Use of medication for obstructive airway
disease
16.6 59.3 <0.001 15.1 43.6 <0.001 0.196
Family history of obstructive airway disease 14.9 32.0 0.042 25.0 30.6 0.223 1.000
Previous contact with health care due to
respiratory symptoms
27.3 59.3 0.001 27.6 54.1 <0.001 0.671
Bold text indicates statistical significance.
a Not AO versus GOLDII in non-smokers.
b Not AO versus GOLDII in ever-smokers.
c GOLDII in non-smokers versus ever-smokers.
COPD among non-smokers 985were classified as having airway obstruction when the LLN
was used for defining obstruction. A previous study in ages
22e72 years, the former ERS-criteria30 and the fixed ratio
of 0.7 also resulted in a similar prevalence of airway
obstruction, about 14%, among all studied and 6e7% among
non-smokers.5 The former ERS-criteria yielded a prevalence
of 12.5% in an Italian study in similar ages.31 Results from
the BOLD studies in middle aged and elderly suggest lower
prevalence estimates of airway obstruction when using the
LLN compared with the fixed ratio.32
Our observation that increasing age is a risk factor for
airway obstruction in non-smokers, as well as for COPD in
general, is in accordance with previous findings,19,33 yet the
relationship with sex is not entirely clear. Some studies
have found non-smokers with airway obstruction to be
predominantly male,28,34 while others have found female
sex to be a risk factor.35,36 In our study we found that
although among all subjects with airway obstruction the
proportion of non-smokers was higher in women, the
prevalence of airway obstruction among non-smokers was
similar in men and women and sex was not an independent
risk factor for airway obstruction in non-smokers according
to the multivariate analysis.
On a global scale, exposure to biomass fuel has been
presented as a major risk factor for COPD.9 It has been
proposed that use of biomass fuel could be more prevalent
than previously assumed also in developed countries.37
However, we lacked data to analyze this. More research isneeded to properly evaluate to what degree biomass fuel
might attribute to COPD in high income countries.
In our material a prior history of tuberculosis as a risk
factor of airway obstruction in non-smokers did not reach
statistical significance, although such a trend could be
noted. This can probably be attributed to the low numbers
entailed. Numerous studies have shown a link between
tuberculosis and airway obstruction,34,38e41 which also may
help to explain the higher prevalence of COPD among non-
smokers in developing regions.
When comparing the clinical presentation between the
non-smokers without airway obstruction and GOLD stage
II, the subjects with more severe obstruction had
significantly more symptoms, whereas when comparing
non-smokers without airway obstruction with the non-
smokers with GOLD stage I, no difference was found in
symptoms or co-morbidity. There has been a discussion on
the validity of classifying subjects without known risk
factors or symptoms as part of the COPD syndrome based
on spirometries alone, especially in older subjects.42,43
Others have proposed that the established fact of under-
diagnosis is a greater threat than potential over-
diagnosis,44,45 and we are inclined to agree. It remains
well known that COPD remains underdiagnosed, even in
symptomatic subjects and also among those with a more
severe disease.16,46,47 Thus, subjects who are not obvi-
ously a part of a high risk group can be expected to be at
even greater risk for underdiagnosis.
Table 5 Risk factors (Odds ratios and 95% confidence intervals, CI) among non-smokers for COPD according to GOLD and
GOLDII by multiple logistic regression analysis.
Variables Categories Independent variables Dependent variables
All COPD COPD-GOLDII
OR 95% CI OR 95% CI
Age 50 years 1 1
51e65 years 1.69 0.78e3.68 1.24 0.39e3.96
66 years 5.56 2.53e12.21 6.06 2.09e17.61
Sex Men 1 1
Women 0.82 0.41e1.65 1.27 0.47e3.62
Family history of obstructive
airway disease
No 1 1
Yes 1.81 0.88e3.73 2.90 1.12e7.53
Environmental tobacco smoke No 1 1
At home 1.02 0.55e1.89 0.49 0.20e1.23
Area of domicile Rural 1 1
Urban 1.08 0.48e2.41 1.06 0.33e3.44
Physician-diagnosed asthma No 1 1
Yes 2.96 1.44e6.08 5.91 2.39e14.60
Socio-economic group Academics 1 1
Manual workers in
industry 0.86 0.32e2.29 1.27 0.23e7.00
service 0.67 0.27e1.69 1.60 0.37e6.96
Assistant non-manual employees 1.28 0.52e3.16 3.47 0.81e14.80
Self-employed 0.88 0.24e3.24 1.74 0.23e13.04
Housewives and others 0.84 0.19e3.70 0.78 0.06e10.12
Unknown 1.07 0.25e4.62 2.77 0.44e17.44
Bold text indicates statistical significance.
986 S. Hagstad et al.Among the non-smokers with GOLD stage II, 26% had
a history of rhinitis and 59% reported any nasal symptoms,
while among ever-smokerswith the samedisease severity 15%
had a history of rhinitis and 40% had any nasal symptoms. This
could indicate a different phenotype for the non-smokerswho
develop chronic obstruction. One study of COPD in non-
smokers with in depth examinations of sputum and radiolog-
ical profiles found evidence of two subgroups divided by
sputum profiles. One group showed significant sputum eosin-
ophilia and the other group had a raised neutrophilic sputum
count. In the former group, although a quarter of the subjects
had positive allergen-specific IgE, there was no underlying
evidence of pre-existing asthma. The latter group showed
a high prevalence of organ-specific autoimmune disease. This
would indicate that there could be various underlying causes
of chronic obstruction in non-smokers.48
More than a half of the non-smokers (59%) with GOLD
stage II reported that they had previously been in contact
with either their primary care physician or a hospital due to
respiratory symptoms as opposed to 27% of those without
airway obstruction. In addition, among non-smokers with
GOLD stage II 59% reported a history of use of medication
for obstructive airway disease as opposed to one out of six
subjects without airway obstruction. Among the ever-
smokers, 44% with GOLD stage II reported past or present
use of any medication for obstructive airway disease. This
might be due to the fact that when these surveys were con-
ducted, there were fewer therapeutic alternatives for thetreatment of COPD. Whatever the cause, the figures imply
that the group as a whole does suffer more from their
condition regardless of the underlying diagnosis.
Using multiple logistic regression analysis we found
increasing age, a previous diagnosis of asthma and a family
history of obstructive airway disease to be statistically
significant risk factors for airway obstruction in non-smokers,
but not exposure to environmental tobacco smoke. The
relationship between environmental tobacco smoke and
asthma,49 as well as morbidity in general,50 has been thor-
oughly investigated. However, this relationship has also been
implicated in some studies of COPD.51,52 When viewing some
of the studies focused on COPD in non-smokers, the rela-
tionship between airway obstruction and environmental
tobacco smoke is not established in some studies11,26 while
others have found environmental tobacco smoke to be a risk
factor.28 These conflicting results might be associated with
the size of the study population. To ensure that the sample
size is sufficient to infer valid statistical relationships, wewill
in upcoming studies increase the statistical power by pooling
data from several cohorts in order to study the impact of
potential risk factors for COPD in non-smokers, such as
environmental tobacco smoke, living close to heavy traf-
ficked roads and other possible risk factors for COPD.
As in all studies of COPD among non-smokers, some
doubt remains whether all non-smokers with airway
obstruction in our study should be diagnosed specifically
with COPD, or if some or even several of them should be
COPD among non-smokers 987labelled with another diagnosis. In our material half of the
non-smokers fulfilling the spirometric criteria of GOLD had
a diagnosis of obstructive airway disease. Of them the
majority were classified as having or having had asthma.
Thus some could have or have had an asthma that pro-
gressed into chronic obstruction as asthma has been iden-
tified as a risk factor of COPD.53 However, that half of the
non-smokers with GOLD stage II had no diagnosis of any
obstructive lung disease at all this implies that the total
burden of disease fail to receive appropriate attention.
Strengths of this study include the total number of
subjects involved, exact spirometry and accurate mapping
of risk factors. Limitations of this study include the low
numbers of non-smokers with COPD, especially those with
more severe obstruction, as well as lack of data of exposure
to biomass fuel and occupationally related noxious gases.
We conclude that a substantial proportion of the
subjects fulfilling the criteria of COPD according to GOLD
had never smoked, and half of the non-smokers with GOLD
stage II had no prior diagnosis of any obstructive lung
disease. Airway obstruction in non-smokers was associated
with increasing age, but no gender difference was found.
The non-smokers with GOLD stage II had significantly
more symptoms than non-smokers without airway obstruc-
tion as well as significantly more co-morbid conditions. The
origin of airway obstruction in non-smokers in western
countries is still not well understood.
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